LA
PTLA

Lee Ainslie’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Lee Ainslie’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-52,425
Closed -$1.25M – 561
2019
Q4 		$1.25M Buy
+52,425
New +$1.45M 0.02% 304

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Lee Ainslie's PTLA Position: Q1 2020 in Review

Lee Ainslie sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 52,425 shares — an estimated $1.25M sold.

Lee Ainslie first reported a position in PTLA in Q4 2019 and held it in 1 quarter. The position peaked at $1.25M in Q4 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Lee Ainslie reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Lee Ainslie sold 52,425 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.25M.
  • Lee Ainslie first reported a position in Portola Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Lee Ainslie's Portola Pharmaceuticals, Inc. position peaked at $1.25M in Q4 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Maverick Capital's 13F filing for Q1 2020, filed 15 May 2020.